MedTrace Logo

Post-Market Clinical Investigation of NanoFUSE® Bioactive Matrix

NCT03762811 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-12-04

No results posted yet for this study

Summary

This purpose of this study is to determine fusion rates and compare clinical outcomes of the NanoFUSE® Bioactive Matrix during post-market clinical use.

Conditions

  • Bone; Degeneration

Interventions

DEVICE

NanoFUSE® Bioactive Matrix

NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.

Sponsors & Collaborators

  • NanoFUSE Biologics, LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2021-03-31
Completion
2021-03-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03762811 on ClinicalTrials.gov